CHRS - Coherus BioSciences Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

687.9M

Cash

144.7M

Avg Qtr Burn

-61.17M

Short % of Float

17.88%

Insider Ownership

1.61%

Institutional Own.

92.78%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CIMERLI (CHS-201) (Lucentis biosimilar) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
YUSIMRY (CHS-1420) (Humira® Biosimilar (adalimumab)) (Anti-TNF) Details Arthritis, Psoriasis, Inflammatory disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details Cancer, Chemotherapy-induced neutropenia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Toripalimab (anti-PD-1 antibody) + Chemotherapy Details Nasopharyngeal carcinoma	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Toripalimab (anti-PD-1 antibody)(JUPITER-06) + Chemotherapy Details Esophageal Squamous Cell Carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details Solid tumor/s, Non-small cell lung carcinoma, Hepatocellular carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CHS-131 Details Multiple sclerosis, Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Toripalimab (CHS-305) Biosimilar (bevacizumab) + Chemotherapy Details Cancer, Small cell lung cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Toripalimab (CHS-305) Biosimilar (bevacizumab) + anti-TIGIT Details Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.